Product
Supplier
Encyclopedia
Inquiry
Semaglutide** buy - large image1
Semaglutide** buy - image1
Semaglutide** buy - image2
Semaglutide** buy - image3
Semaglutide** buy - image4
Semaglutide** buy - image5

Semaglutide**

Unit Price:

$28-30/MT FOB

Get Latest Price
Grade:

Industrial Grade

Content:

99.99%

Port:

shenzhen

Packaging:

5mg*10vials 10mg*10vials 15mg*10vials 20mg*10vials 30mg*10vials 40mg*10vials 50mg*10vials 60mg*10vials 100mg*10vials

Price valid (until):

2026-11-18

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents
Average Lead Time:
1 days
Qualification:
Main Products:

Tirzepatide,Retatrutide,Semaglutide

  • Product Details

  • Seller Information

  • Description


      Product Detail  


    Pls input...

    WA+852 5534 2975

    Product Introduction

    Semaglutide is a long‑acting GLP‑1 receptor agonist peptide. Our product is lyophilized peptide powder intended solely for laboratory research. FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY MEDICAL USE.

    Chemical Specifications

    • CAS No.: 910463‑68‑2
    • Sequence: Synthetic peptide
    • Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
    • Molecular Weight: 4113.58 g/mol
    • Appearance: White lyophilized powder
    • Purity: ≥98% as tested by HPLC
    • Solubility: Soluble in bacteriostatic water
    • Common packing: 5mg,10mg,15mg,20mg per borosilicate glass vial

    Research Applications

    Semaglutide is mainly used for pre‑clinical laboratory research related to GLP‑1 receptor study, metabolism regulation, appetite control and weight‑management‑related experiments. It can be reconstituted with Bacteriostatic Water under aseptic laboratory conditions.

    Storage & Reconstitution Notes

    1. Unopened vials: Store at ‑20℃, keep dry, sealed and away from light, avoid moisture.
    2. After reconstitution: Refrigerate at 2‑8℃, use within 28 days. Do not allow repeated freeze‑thaw cycles.
    3. Reconstitute by slowly adding BAC‑Water along vial inner wall, swirl gently to dissolve. Violent shaking will cause peptide degradation.

    Short business snippet(for development email / price list)

    Semaglutide, ≥98% HPLC purity, white lyophilized peptide powder in glass vials. For research use only. Used for GLP‑1 related metabolism research. Batch‑specific COA can be provided on request.

    Items Specifications






    Basic Info
    Product Name:

    fit

    Categories:

    Polypeptide

    Research
    Class:

    GLP-1R agonist

    Status:

    FDA-approved (Ozempic / Wegovy / Rybelsus)

    Mechanism:

    Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.

    Activity note:

    Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).

    Source:

    Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI

    Clinical Development:

    NCT03548935; NCT03552757; NCT01720446; NCT02692716

    FDA:

    Ozempic, Wegovy, Rybelsus (approved 2017-12-05)

    References
    ChEMBL:

    CHEMBL2108724

    DrugBank:

    DB13928

    KEGG DRUG:

    D10025

    PubChem:

    PubChem

    Disclaimer:

    Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Tirzepatide,Retatrutide,Semaglutide

    Location:

    Unit 1207, Elevator 1, Office Tower A2, Wanda Plaza, No. 8 Aojiang Road, Taijiang District, Fuzhou City, Fujian Province

    Payment Terms:

    TT against copy of documents

    Average lead Time:

    1 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    5-10

    Year of Establishment:

    2024

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product

More from this Seller

pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.